Costeffectiveness analysis of Abiraterone Acetate versus Docetaxel in the management of metastatic castrationsensitive prostate cancer Hong Kongs perspective

Cost-effectiveness analysis of Abiraterone Acetate versus Docetaxel in the management of metastatic castration-sensitive prostate cancer: Hong Kong’s perspective

More From BioPortfolio on "Cost-effectiveness analysis of Abiraterone Acetate versus Docetaxel in the management of metastatic castration-sensitive prostate cancer: Hong Kong’s perspective"